ChemicalBook > CAS DataBase List > Regorafenib-13C-d3

Regorafenib-13C-d3

Product Name
Regorafenib-13C-d3
CAS No.
2126178-55-8
Chemical Name
Regorafenib-13C-d3
Synonyms
Regorafenib-13C-d3;4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-(methyl-13C-d3)-2-pyridinecarboxamide
CBNumber
CB92675548
Molecular Formula
C21H12ClD3F4N4O3
Formula Weight
486.842898134
MOL File
2126178-55-8.mol
More
Less

Regorafenib-13C-d3 Property

storage temp. 
Store at -20°C
solubility 
DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 14 mg/ml
form 
A solid
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
25486
Product name
Regorafenib-13C-d3
Purity
≥99% deuterated forms (d1-d3)
Packaging
500μg
Price
$242
Updated
2024/03/01
Cayman Chemical
Product number
25486
Product name
Regorafenib-13C-d3
Purity
≥99% deuterated forms (d1-d3)
Packaging
1mg
Price
$459
Updated
2024/03/01
AK Scientific
Product number
0135DY
Product name
4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-(trideuterio(113C)methyl)pyridine-2-carboxamide
Packaging
1mg
Price
$610
Updated
2021/12/16
More
Less

Regorafenib-13C-d3 Chemical Properties,Usage,Production

Description

Regorafenib-13C-d3 is intended for use as an internal standard for the quantification of regorafenib by GC- or LC-MS. Regorafenib is an orally bioavailable multi-kinase inhibitor with anticancer activity.1 It inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ with IC50 values of 1.5, 2.5, 4.2, 7, 13, and 22 nM, respectively. Regorafenib also inhibits B-RAF, VEGFR3, FGFR, and Tie2 (IC50s = 28, 46, 202, and 311 nM, respectively) as well as other kinases.1,2,3 In vivo, regorafenib (10 mg/kg) reduces tumor size in the MDA-MB-231 breast and 786-O renal cancer mouse xenograft models.1 It also reduces tumor microvessel area and inhibits tumor growth in a panel of mouse xenograft models. Formulations containing regorafenib have been used in the treatment of advanced gastrointestinal stromal tumors and metastatic colorectal cancer.

References

1. Wilhelm, S.M., Dumas, J., Adnane, L., et al. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Int. J. Cancer 129(1),245-255(2011).
2. Uitdehaag, J.C.M., de Roos, J.A.D.M., van Doornmalen, A.M., et al. Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use PLoS One 9(3),1-13(2014).
3. Ravi, S., and Singal, A.K. Regorafenib: An evidence-based review of its potential in patients with advanced liver cancer Core Evid. 9,81-87(2014).

Regorafenib-13C-d3 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Regorafenib-13C-d3 Suppliers

CHINA 11 United States 2 Global 13
TargetMol Chemicals Inc.
Tel
+8613564774135
Email
zijue.cai@tsbiochem.com
Country
United States
ProdList
19881
Advantage
58
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81

2126178-55-8, Regorafenib-13C-d3Related Search:


  • Regorafenib-13C-d3
  • 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-(methyl-13C-d3)-2-pyridinecarboxamide
  • 2126178-55-8